Medical technology company Masimo (NASDAQ:MASI) announced on Monday that independent researchers in New Delhi, India have investigated the accuracy of its RRp with the Rad-G Pulse Oximeter in paediatric patients versus clinician-determined values and have published the promising results in Pneumonia.
Masimo added that researchers sought to determine whether a "multi-modal" pulse oximeter, Masimo Rad-G, could accurately measure respiration rate. Rad-G uses a single Masimo SET pulse oximetry sensor to measure both SpO2 and RRp, as well as pulse rate (PR), perfusion index (Pi) and pleth variability index (PVi).
Under the study, the company said its researchers have used Rad-G, alongside traditional paediatrician assessment, to measure the respiration rate of 97 children admitted to the outpatient and emergency departments at Kalawati Saran Hospital in New Delhi, over two weeks. They analyzed the level of agreement between plethysmography-based respiration rate (RRp) and the clinicians' assessment of respiration rate.
According to the company, the researchers found that RRp and the control respiration rate measurement method showed "significant strong association (97%) and that values obtained either from pulse oximeter or by paediatrician (gold standard) are very close to each other.
In addition, the Masimo RRp is reportedly CE marked and the US FDA 510(k) clearance is pending.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT